Jaime Sanz-CÃ;novas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8963235/publications.pdf

Version: 2024-02-01

		1477746	1372195
11	112	6	10
papers	citations	h-index	g-index
12	12	12	110
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study. Annals of Medicine, 2019, 51, 252-261.	1.5	25
2	Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency – Three consecutive cases and review of the literature. Enfermedades Infecciosas Y MicrobiologÃa ClĀnica, 2022, 40, 507-516.	0.3	21
3	Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure. Journal of the American Geriatrics Society, 2022, 70, 862-871.	1.3	10
4	Statin Therapy in Very Old Patients: Lights and Shadows. Frontiers in Cardiovascular Medicine, 2021, 8, 779044.	1.1	7
5	Glucagon-like peptide-1 receptor agonists and sodiumâ [^] glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect. European Journal of Internal Medicine, 2022, 96, 26-33.	1.0	7
6	Metabolically healthy obesity: Inflammatory biomarkers and adipokines in elderly population. PLoS ONE, 2022, 17, e0265362.	1.1	7
7	Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure. Journal of Clinical Medicine, 2021, 10, 3540.	1.0	6
8	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice. Frontiers in Endocrinology, $0,13,13$	1.5	6
9	Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain. International Journal of Environmental Research and Public Health, 2020, 17, 6845.	1.2	4
10	De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study. Journal of Clinical Medicine, 2021, 10, 2013.	1.0	2
11	Lifestyle Modification Program on a Metabolically Healthy Elderly Population with Overweight/Obesity, Young-Old vs. Old-Old. CONSEQUENCES of COVID-19 Lockdown in This Program. International Journal of Environmental Research and Public Health, 2021, 18, 11926.	1.2	2